Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once
weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with
type 2 diabetes mellitus.
To examine the long-term (52 weeks of treatment) safety and effect on glucose control of
exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.